Abstract
Alopecia areata (AA) is an autoimmune disease characterized by nonscarring hair loss. As a clinically heterogeneous disease, various classification systems have evolved for defining its severity. In this high-level review of the literature, we discuss the traditional classification systems for AA severity and their strengths and weaknesses. Most recent classifications have focused on the extent of scalp hair loss as a defining feature, but additional clinical aspects of the disease, including location, pattern, and duration of hair loss as well as impact on the patient’s quality of life, are also relevant. These various components have typically been used unidimensionally to classify patients. We propose a multidimensional framework to define AA severity that incorporates multiple patient- and illness-related domains. Using such a framework, dermatologists may better assess the severity of the disease for the individual patient beyond the extent of hair loss.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Senna, Maryanne M. 2 ; Ohyama, Manabu 3 ; Tosti, Antonella 4 ; Sinclair, Rodney D. 5 ; Ball, Susan 6 ; Ko, Justin M. 7 ; Glashofer, Marc 8 ; Pirmez, Rodrigo 9 ; Shapiro, Jerry 10 1 Yale School of Medicine, Department of Dermatology, New Haven, USA (GRID:grid.47100.32) (ISNI:0000000419368710)
2 Massachusetts General Hospital and Harvard Medical School, Department of Dermatology, Boston, USA (GRID:grid.32224.35) (ISNI:0000 0004 0386 9924)
3 Kyorin University, Department of Dermatology, Faculty of Medicine, Mitaka-shi, Japan (GRID:grid.411205.3) (ISNI:0000 0000 9340 2869)
4 University of Miami, Dr. Philip Frost Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, Miami, USA (GRID:grid.26790.3a) (ISNI:0000 0004 1936 8606)
5 Sinclair Dermatology, Victoria, Australia (GRID:grid.477890.5)
6 Eli Lilly and Company, Indianapolis, USA (GRID:grid.417540.3) (ISNI:0000 0000 2220 2544)
7 Stanford University School of Medicine, Department of Dermatology, Stanford, USA (GRID:grid.168010.e) (ISNI:0000000419368956)
8 Schweiger Dermatology Group, West Orange, USA (GRID:grid.492927.3) (ISNI:0000 0004 7668 3952)
9 Instituto de Dermatologia Professor Rubem David Azulay, Santa Casa da Misericórdia do Rio de Janeiro, Centro de Estudos dos Cabelos, Rio de Janeiro, Brazil (GRID:grid.492927.3)
10 New York University Grossman School of Medicine, The Ronald O. Perelman Department of Dermatology, New York, USA (GRID:grid.240324.3) (ISNI:0000 0001 2109 4251)





